In re Patent Application of

, HAYNES et al

Serial No. 10/664,029

Filed:

September 17, 2003

Title:

IMMUNOGEN COMPRISING AN HIV ENVELOPE PROTEIN, A LIGAND AND H2

PEPTIDE (AS AMENDED)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

	☐ Correspondence Address Indication Form Attached.		
	Fees are attached as calculated below: Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$50.00 \$0.00 (1202)/\$0.00 (2202)	\$	
	Independent claims after amendment previously paid for 3 (at least 3) = 0 minus highest number $0 \times 200.00 \times 200.0$	\$	
	If proper multiple dependent claims now added for first time, (ignore improper); add \$360.00 (1051)/\$180.00 (2051) Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) One Month Extension \$120.00 (1251)/\$60.00 (2251) Two Month Extensions \$450.00 (1252)/\$225.00 (2252)	\$	
4	Three Month Extensions \$1020.00 (1253/\$510.00 (2253) Four Month Extensions \$1590.00 (1254/\$795.00 (2254)	\$	
•	Terminal disclaimer enclosed, add \$130.00 (1814)/ \$65.00 (2814)	\$	
	☐ Applicant claims "small entity" status. ☐ Statement filed herewith		
	Rule 56 Information Disclosure Statement Filing Fee \$180.00 (1806)	\$	180.00
	Assignment Recording Fee \$40.00 (8021) Other:	\$ \$	
	TOTAL EEE ENCLOSED	Œ	180 00

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

942874

TEW 14

Atty Dkt. 1579-804

C#

TEED STATES PATENT AND TRADEMAR

1648

Examiner: Stucker, J.J.

Date: April 8, 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

HAYNES et al

Serial No. 10/664,029

Filed: September 17, 2003

For: IMMUNOGEN COMPRISING AN HIV ENVELOPE PROTEIN, A LIGAND AND H2

0 8 2005

PEPTIDE (AS AMENDED)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 April 8, 2005

Atty. Ref.:

Examiner:

Group:

Confirmation No. 2598

1579-804

Stucker, J.J.

1648

Sir:

INFORMATION DISCLOSURE STATEMENT

1. PTO-1449 Pursuant to 37 CFR 1.97(b)
[within 3 months of filing or prior to 1st Office Action on the merits]

N/C

- 2.(a) Statement Pursuant to 37 CFR 1.97(c)
 [before Final Office Action or Allowance (requires Rule 97(e)
 Statement or Rule 17(p) fee)] N/C
- 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c)
 [before Final Office Action or Allowance (requires Rule 97(e)
 Statement or Rule 17(p) fee)] \$180.00
- 9. Pursuant to 37 CFR 1.97(d)
 [after Final Office Action or Allowance (requires Rule 97(e)
 Statement and Rule 17(p) fee), but before final fee payment]
 \$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of docs on Form PTO-1449 w/copies (where required) of each doc. and translation or concise explanation of non-English docs. (e.g., Search Rpt.) is enclosed (Cruse et al was cited by the Ex. in related Appln. 10/646,729 – a copy is not attached as no copy is in Applicants' file).

음

04/12/2005 RBEYENE1 00000057 10664029

HAYNES et al Serial No. 10/664,029 April 8, 2005

This p	paper	s submitted in accordance with:							
	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]							
\boxtimes	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier] and							
		a) The required Statement made in item 8 below; or							
	\boxtimes	b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.							
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and							
		a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and							
		b) The required Statement is stated in item 8 below.							
	8.	Statement under 37 CFR 1.97(e)							
		a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or							
		b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.							
\boxtimes	9.	Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.							

HAYNES et al Serial No. 10/664,029 April 8, 2005

Respectfully submitted, NIXON & VANDERHYE P.C.

Bv:

Mary J\ Wilson

Reg. No. 32,955

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000

Facsimile: (703) 816-4100

				10 6.2	•				
Sheet	1	of , 8		APR 0 8 2005 5.)				
INFO	ORM	ATION DISCLOSU	IRE ATTY. D	OOCKET NOTE TRADEMINIST	SERIA	AL NO.			
		CITATION	1579-	-804	10/6	64,029			
			APPLIC	ANT				,	
				NES et al					
	(Use s	everal sheets if necessary)	FILING	DATE	GROU	JP			
			<u>.</u>	ember 17, 2003	164	8			
				U.S. PATENT DOCUMEN	NTS				_
*EXAMINE INITIAL	R	DOCUMENT NUMBE	R DATE	NAME		CLASS	SUBCLASS	FILING	
INITIAL		5,518,723	5/1996	DeVico et a	ſ		00002100		
		5,843,454	12/1998	Devico et a					
	<u> </u>				·	<u> </u>			
	+					1			
			-	-				· · · · · · · · · · · · · · · · · · ·	
-	+					-			
	\top			· ·					
·	_								
	+					}			
	+				<u> </u>				
			.						
			FO	REIGN PATENT DOCUM	MENTS				
		DOCUMENT	DATE	COUNTRY		CLASS	SUBCLASS	TRANS YES	LATION NO
	٠.								
	-					<u> </u>			
	+					1			
	+								
				including Author, Title, [
				Structural Analysis of So					
		Human Retrovirus		Neutralization-Susceptible	e Primary HIV	Type i iso	plates , AID	s Resea	arch and
				of the coreceptor-binding s	ite in a CD4-in	depender	nt HIV-1 env	elope p	rotein",
		Proc. Natl. Acad. S	Sci. USA 96:635	59-6364 (1999)					
		Golding et al, "Pho	rbol Ester-Indu	ced Down Modulation of T	Failless CD4 R	eceptors	Requires Pr	ior Bindi	ing of
	+	gp izo aliu Sugges	oto a INDIE IDI A	ccessory Molecules , Jour	nai oi viiology	03(10).0	1-0-0140 (1	333)	
	\perp								
	+								
*Examine	r			Date Co	nsidered				

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Date Considered

*Examiner

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	Serial No.	
1579-804		
Applicant		_

(Use several sheets if necessary)		Filing Date Group					
		Septembe	er 17, 2003	1648	•		
		U.S. P	ATENT DOCUMENTS	,			
*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	CLIDCI ACC	FILING	DATE
INITIAL T	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	TE APPRO	OPRIATE
					-		
						 	
	-						
		FOREIGN	PATENT DOCUMENTS				
						TRANS	LATION
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
			× .				
					<u> </u>		
						L	L
			ng Author, Title, Date, Pe				
			ve conformation of HIV-1 g				(1007)
			" Broad Neutralization of Pri y Virus Type 1 Human Mone				
			ntify Mimotopes from Recor				
	Research and Human Re	troviruses 13(18):1:	549-1559 (1997)	momant i nage i epi	ilde Display	Libraries	, AIDS
			mediated by multiple region	ns within both the v	iral envelope	and the	CCR-5
	co-receptor", The EMBO	O Journal 16(10):259	99-2609 (1997)		•		
			ike domain of human immur				
			rather than assembly of the	glycoprotein comp	lex", Proc. N	atl. Acad	l. Sci.
	USA 91:12676-12680 (1		ne of an Unusual Macropha	ge Tranic and High	ly Cytonathi	o Strain	·£
	Human Immunodeficien	cv Virus Type 1". Jo	ournal of Virology 66(12):75	ge-110pie and 111gii 517-7521 (1992)	пу Суюрани	Couamic	<i>)</i> 1
			nocyte positive selection", L		1:616-620 (1	996)	
			ries Suitable for Use in the E	BIAcore Surface Pla	smon Reson	ance Det	ector",
	Analytical Biochemistry						
			Subunit Vaccine Products I				
	(1996)	Not Primary Isolate	s of Human Immunodeficier	ncy Virus Type I", .	J. Infect. Dis.	173:340	-348
		ved HIV on 120 Gly	coprotein Structure Involved	l in Chemokine Dec	entor Rindin	a" Scier	
	280:1949-1953 (1998)	ved III v gp120 Giy	coprotein structure involved	i iii Chemokine Rec	cptor Bindin	ig , selen	ice
							
		<u></u>		·			
Examiner			Date Considere	a l			

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 4 .of 8.

INFORM	ATION DISCLOSU	RE ATTY.D	OCKET NO.	SERIAL NO.			
	CITATION	1579-		10/664,029			
		APPLICA	ANT				
			IES et al				_
(Use se	everal sheets if necessary)	FILING D	DATE	GROUP			,
			mber 17, 2003	1648			· <u> </u>
		U.S.	PATENT DOCUMENTS				
'EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		OPRIATE
	5,019,387	5/1991	Haynes et al				
	5,013,548	5/1991	Haynes et al				
	5,352,576	10/1994	Haynes et al				-
	5,993,819	11/1999	Haynes et al				
	5,516,632	5/1996	Palker et al				
			·				
		FORE	IGN PATENT DOCUMEN	TS			
							TRACT
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	WO 95/29700	11/1995	PCT				
	WO 97/14436	4/1997	PCT				
	WO 93/15750	8/1993	PCT				
	WO 02/024149	3/2002	PCT				
	WO 01/56355	8/2001	PCT				
	OTHER DOCUM	ENTS (inc	luding Author, Title, Date	e, Pertinent pa	ages, etc.)	
						• • • • • • • • • • • • • • • • • • • •	
1 1			Market				
ļ							
xaminer			Date Considered				

Sheet 5 , of 8.

NFORMATION DISCLOSURE	ATTY, DOCKET NO.		SERIAL NO.								
CITATION	1579-804 APPLICANT		10/664,029								
	HAYNES et al										
(Use several sheets if necessary)	FILING DATE		GROUP								
	September 17,	2003	1648								
	U.S. PATENT	T DOCUMENTS	-								
XAMINER					FILING DAT						
INITIAL DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPROPRIA						
OTHER DOCUMEN											
OTHER DOCUMEN											
Trkola et al, "Human Mon											
Glycoprotein of Human In											
Mo et al, "Human Immuno			cape Neutralizati	ion by Hum	an Monocio						
	Antibody IgG1b12", Journal of Virology 71(9):6869-6874 (1997)										
	Ye et al, "Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Similar Human Immunodeficiency Virus Resistance in Advisor Virus Resistance in Advisor Virus Resistance in Advisor Virus Resistance in Advisor										
	Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus Passaged In Vivo", Journal of Virology 74(24):11955-11962 (2000)										
	Fouts et al, "Neutralization of the Human Immunodeficiency Virus Type 1 Primary Isolate JR-FL by Human										
	Monoclonal Antibodies Correlates with Antibody Binding to the Oligomeric Form of the Envelope Glycoprote										
	Complex", Journal of Virology 71(4):2779-2785 (1997)										
	Sullivan et al, "CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120										
	Glycoprotein: Consequences for Virus Entry and Neutralization", Journal of Virology 72(6):4694-4703 (1998)										
Moore et al, "Exploration	Moore et al, "Exploration of antigenic variation in gp120 from clades A through F of human immunodeficien										
	virus type 1 by using monoclonal antibodies", Journal of Virology 68(12):8350-8364 (1994) – Abstract										
	Jiang et al, "A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human										
	Immunodeficiency Virus Type 1 Envelope Glycoprotein", Journal of Virology 72(12):10213-10217 (1998)										
Rimsky et al, "Determinar	Rimsky et al, "Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitor										
Peptides", Journal of Viro	Peptides", Journal of Virology 72(2):986-993 (1998)										
Earl et al, "Immunogenicit	Earl et al, "Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1										
	gp140", Journal of Virology 75(2):645-653 (2001)										
	Muster et al, "A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1", Journal of Virology 67(11):6642-6647 (1993). Abstract										
	Virology 67(11):6642-6647 (1993) – Abstract Cormier et al. "Specific interaction of CCR5 amino-terminal domain pentides containing sulfaturesines with										
	Cormier et al, "Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope alvoorotein ap 120" PNAS 97(11):5762-5767 (2000)										
	HIV-1 envelope glycoprotein gp120", PNAS 97(11):5762-5767 (2000) Hoffman et al, "A biosensor assay for studying ligand-membrane receptor interactions: Binding of antibodies										
	and HIV-1 Env to chemokine receptors", PNAS 97(21):11215-11220 (2000)										
	Myszka et al, "Energetics of the HIV gp120-CD4 binding reaction", PNS 97(16):9026-9031 (2000)										
i i iviyszka et al, "Energetics	Roben et al, "Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site										
		D4 binding reaction",									
	properties of a pane	D4 binding reaction", el of human recombin	ant Fab fragmen	ts to the CD	4 binding s						
Roben et al, "Recognition	properties of a pane ng abilities to neutra	D4 binding reaction", el of human recombin	ant Fab fragmen	ts to the CD	4 binding s						
Roben et al, "Recognition of gp120 that show differing 68(8):4821-4828 (1994) – Muster et al, "Cross-neutrong from the company of the company	properties of a panding abilities to neutral Abstract alizing activity again	D4 binding reaction", el of human recombinalize human immunodens est divergent human in	ant Fab fragment eficiency virus typ nmunodeficiency	ts to the CD be 1", Journ virus type	04 binding s al of Virolog 1 isolates						
Roben et al, "Recognition of gp120 that show differing 68(8):4821-4828 (1994) — Muster et al, "Cross-neutrinduced by the gp41 sequence for all the sequence of	properties of a panding abilities to neutral Abstract alizing activity again ence ELDKWAS", J	D4 binding reaction", el of human recombinalize human immunode est divergent human in lournal of Virology 68(ant Fab fragment eficiency virus typen nmunodeficiency 6):4031-4034 (19	ts to the CE be 1", Journ virus type 994) – Abst	04 binding s al of Virolog 1 isolates ract						
Roben et al, "Recognition of gp120 that show differing 68(8):4821-4828 (1994) — Muster et al, "Cross-neutrinduced by the gp41 sequence of the	properties of a panding abilities to neutral Abstract alizing activity again ence ELDKWAS", Jeric human immunoc	D4 binding reaction", el of human recombinalize human immunode est divergent human in lournal of Virology 68(deficiency virust type 1	ant Fab fragment eficiency virus typen mmunodeficiency (6):4031-4034 (19 envelope glycop	ts to the CE be 1", Journ virus type 994) – Abst protein elicit	04 binding s al of Virolog 1 isolates ract						
Roben et al, "Recognition of gp120 that show differing 68(8):4821-4828 (1994) — Muster et al, "Cross-neutrinduced by the gp41 sequences."	properties of a panding abilities to neutral Abstract alizing activity again ence ELDKWAS", Jeric human immunoc	D4 binding reaction", el of human recombinalize human immunode est divergent human in lournal of Virology 68(deficiency virust type 1	ant Fab fragment eficiency virus typen mmunodeficiency (6):4031-4034 (19 envelope glycop	ts to the CE be 1", Journ virus type 994) – Abst protein elicit	04 binding s al of Virolog 1 isolates ract						
Roben et al, "Recognition of gp120 that show differing 68(8):4821-4828 (1994) - Muster et al, "Cross-neutrinduced by the gp41 sequence bear et al, "Native oligomes"	properties of a panding abilities to neutral Abstract alizing activity again ence ELDKWAS", Jeric human immunoc	D4 binding reaction", el of human recombinalize human immunode est divergent human in lournal of Virology 68(deficiency virust type 1	ant Fab fragment eficiency virus typen mmunodeficiency (6):4031-4034 (19 envelope glycop	ts to the CE be 1", Journ virus type 994) – Abst protein elicit	04 binding stal of Virolog 1 isolates ract						
Roben et al, "Recognition of gp120 that show differing 68(8):4821-4828 (1994) - Muster et al, "Cross-neutrinduced by the gp41 sequence bear et al, "Native oligomes"	properties of a panding abilities to neutral Abstract alizing activity again ence ELDKWAS", Jeric human immunoc	D4 binding reaction", el of human recombinalize human immunode est divergent human in lournal of Virology 68(deficiency virust type 1	ant Fab fragment eficiency virus typen mmunodeficiency (6):4031-4034 (19 envelope glycop	ts to the CE be 1", Journ virus type 994) – Abst protein elicit	04 binding stal of Virolog 1 isolates ract						

Form PTO-FB-A820 (Also PTO-1449)

INFORMATION DISCLOSURE

CITATION

Atty. Docket No.	Serial No.	
1579-804	10/664,029	
Applicant		
HAYNES et al		

(Use several sheets if necessary)		Filing	Date		Grou	ip			
		Sept	tember 17, 2	2003	164	18			
					1-				
*EXAMINER			U.S. PAIENI	DOCUMENTS				FILING	DATE
INITIAL	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	IF APPRO	PRIATE
		<u> </u>			w .				
									
						 			
	<u>k</u> , ,	FOI	REIGN PATEN	T DOCUMENTS			<u> </u>		
			·					TRANS	LATION
	DOCUMENT	DATE		COUNTRY		CLASS	SUBCLASS	YES	NO
				. ' '. '.		T			
				durities.					
		<u> </u>							
		<u> </u>				 			
	07:177.700		<u> </u>			1			
	Robertson et al, Recom			or, Title, Date, P			(C.)		
	Shu et al, Helical Intera						tory Activity	of gn41	
	Peptides, Biochemistry			io ito voui siruotutu	. Du oio 10			01 85	
	Abaza and Atassi, "Eff								onal
	Antibodies of Predeter						with Region	ı 94-100	
	(Antigenic Site 3) of M Cohen et al, "Pronounc						" Proc Natl	Acad S	ci IISA
	96:10842-10847 (1999		iunosuppression	in vivo inculated o	y III v I a	t chancinge	, Troc. Ivani.	Acad. D	ci. OSA
_	Cruse et al, Illustrated		Immunology (B	oca Raton, FL, CR	C Press,	Inc.), p. 309	9 (1995), QR	180.4.C7	8
	Paul, Fundamental Imn								
	Riffkin et al, "A single				fferent ex	tracellular s	serine protea	ses V2 ar	ıd B2
	from Dichelobacter no	aosus", Gene	167:279-283 (1	993)					
				100					
									
	-		· · · · · · · · · · · · · · · · · · ·						
 				Γ	ı				
Examiner				Date Consider	ed				

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Sheet 7 , of 8.

INFORM	ATION DISCLOSU	RE ATTY. DOC	KET NO. SEP	RIAL NO.				
CITATION		1579-804		10/664,029				
		APPLICANT						
		HAYNES		SUID		<u></u>		
(Use several sheets if necessary)		FILING DAT		OUP				
			ber 17, 2003 16	48			_	
*EXAMINER		U.S. P	PATENT DOCUMENTS	 		FILING	3 DATE	
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		OPRIATE	
						 		
					 	 		
_						 		
+					<u> </u>		_	
						 		
						<u></u>		
		FOREIG	IN PATENT DOCUMENTS			TDANC	LATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
T	1			7	1		T	
						 		
	OTHER DOCUM	ENTS (inclu	ding Author, Title, Date, Pei	tinent pa	ages, etc.)		
			ope-CD4 receptor complexes elicit	broadly cro	ss-reactive	neutrali	zing	
			AS 99(18):11842-11847 (2002) erization of a Single-Chain Polypep	tide Analoc	ue of the H	uman		
	Immunodeficiency Viru		0-CD4 Receptor Complex", Journa				36	
	(2000)	A -4:bd:	Deignal against Covalently Constitution	lead Oamal				
			Raised against Covalently Crosslin 20 and CD4 Receptor Identify a No.				pe on	
	gp120", Virology 211:	583-588 (1995)	•	· · · · · · · · · · · · · · · · · · ·		<u> </u>		
			Complexes of Human Immunodefing Immune Response That Includes					
	Virus Ioslates", Virolog			Antibodies	Selective i	OI FIIIII	aı y	
	Vita et al, "Rational en	igineering of a r	miniprotein that reproduces the core	of the CD	4 site intera	cting wif	th HIV-1	
	envelope glycoprotein	", PNAS 96(23)	:13091-13096 (1999)					
							-	
								
Examiner		W	Date Considered					
	f reference considered, whether or with next communication to applica		ormance with MPEP 609; Draw line through citation	n if not in confo	rmance and not	considered.	Include	
	отполня по принос				Form PTO-FB-	A820 (Also	PTO-1449)	

Sheet 8 of 8.

INFORM	ATION DISCLOSU	RE ATTY. DO	OCKET NO.	SERIAL NO.				
CIȚATION		1579-804		10/664,029				
		APPLICA						
(Use s	everal sheets if necessary)	HAYN FILING D	ES et al	GROUP				
(0000)	,,	-	mber 17, 2003	1648				
			PATENT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING	DATE OPRIATE	
1111111	- BOSSINE IV I TOMBE I							
					<u> </u>			
		 						
		FODE	ION DATENT DOCUMENT		•			
		FURE	IGN PATENT DOCUMENTS	5		TRANSI	LATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
	WO 94/15638	7/1994	WIPO					
	WO 00/08043	2/2000	WIPO					
					ļ			
	OTHER DOCUM	ENTS (incl	uding Author, Title, Date,	Pertinent pa	ages. etc.	l }	L	
	Devico et al, "Covaler	ntly Crosslink	ed Complexes of Human Immuno	deficiency Virus	s Type 1 (H	IV-1) gp		
	CD4 Receptor Elicit a lsolates", Virology 218		Immune Response That Includes	Antibodies Sel	ective for P	rimary V	irus	
	Zhang et al, "Antibody	/ 17b Binding	at the Coreceptor Site Weakens	the Kinetics of	the Interacti	on of En	velope	
			chemistry 40:1662-1670 (2001) nan Immunodeficiency Virus Type	1 Posistanca	of and 1 Dor	ivod Inh	ibiton	
	Peptides", Journal of			i i Nesisiance	or gp4 i-Dei	IVEU IIIII	ibitory	
			ges of gp120 in Epitopes near the	CCR5 Binding	Site Are In	duced b	y CD4	
			ochemistry 38:9405-9416 (1999) strained Monoclonal Antibody A32	2-Human Immu	nodeficienc	v Virus (HIV)	
	Env gp120 Complexe	s Compared	to That of Recombinant HIV Type	1 gp120 Envel	ope Glycop	roteins",	,	
	Journal of Virology 78 Boots et al. "Anti-Hum		78 (2004) eficiency Virus Type 1 Human Mo	noclonal Antibe	ndies that B	ind		
	Discontinuous Epitope	es in the Viral	Glycoproteins Can Identify Mimo	topes from Red	combinant P		eptide	
<u> </u>	Display Libraries", AID	OS Research	and Human Retroviruses 13(18):	1549-1559 (199	97)			
								
	 							
kaminer	<u> </u>		Date Considered	1				
	reference considered, whether of ith next communication to applica		onformance with MPEP 609; Draw line through o	citation if not in confo	rmance and not o	considered.	Include	

Form PTO-FB-A820 (Also PTO-1449)